Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10

Biomedicine and Pharmacotherapy

Volumn 66, Issue 5, 2012, Pages 323-329

  Mazzoccoli, Luciano ^a   Cadoso, Silvia H ^a   Amarante, Giovanni W ^a   De Souza, Marcus V N ^a   Domingues, Robert ^b   Machado, Marco A ^b   De Almeida, Mauro V ^a   Teixeira, Henrique C ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b EMBRAPA CERRADOS   (Brazil)

Author keywords

IL 10; Inflammatory response; Thalidomide analog; TNF

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CXCL9 CHEMOKINE; DIAMINE DERIVATIVE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, CD80; CELL LINE; CYTOKINES; DIAMINES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PROCESSING, POST-TRANSCRIPTIONAL; THALIDOMIDE;

EID: 84863993504     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.05.001     Document Type: Article

References (45)

1. Hashimoto Y. Structural development of biological response modifiers based on thalidomide. Bioorg Med Chem 2002, 10:461-479.
2. Old L.J. Tumor necrosis factor (TNF). Science 1985, 230:630-632.
3. Bochud P.Y., Hawn T.R., Siddiqui M.R., Saunderson P., Britton S., Abraham I., et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008, 197:253-261.
4. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173:699-703.
5. Melchert M., List A. The thalidomide saga. Int J Biochem Cell Biol 2007, 39:1489-1499.
6. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91:4082-4085.
7. Faver I.R., Guerra S.G., Su W.P., el-Azhary R. Thalidomide for dermatology: a review of clinical uses and adverse effects. Int J Dermatol 2005, 44:61-67.
8. Paravar T., Lee D.J. Thalidomide: mechanisms of action. Int Rev Immunol 2008, 27:111-135.
9. Rowland T.L., McHugh S.M., Deighton J., Dearman R.J., Ewan P.W., Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998, 40:11-20.
10. Ye Q., Chen B., Tong Z., Nakamura S., Sarria R., Costabel U., Guzman J. Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006, 28:824-831.
11. Morgan G.J., Krishnan B., Jenner M., Davies F.E. Advances in oral therapy for multiple myeloma. Lancet Oncol 2006, 7:316-325.
12. Marriott J.B., Westby M., Cookson S., Guckian M., Goodbourn S., Muller G., et al. Cc-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 1998, 161:4236-4243.
13. Casero R.A., Woster P.M. Terminally alkylated polyamine analogues as chemotherapeutic agents. J Med Chem 2001, 44:1-26.
14. Jayakumar A., Widenmaier R., Ma X., McDowell M.A. Transcriptional inhibition of interleukin-12 promoter activity in leishmania spp.-infected macrophages. J Parasitol 2008, 94:84-93.
15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
16. del Olmo E., Plaza A., Muro A., Martinez-Fernandez A.R., Nogal-Ruiz J.J., Lopez-Perez J.L., et al. Synthesis and evaluation of some lipidic aminoalcohols and diamines as immunomodulators. Bioorg Med Chem Lett 2006, 16:6091-6095.
17. de Almeida M.V., Teixeira F.M., de Souza M.V., Amarante G.W., Alves C.C., Cardoso S.H., et al. Thalidomide analogs from diamines: Synthesis and evaluation as inhibitors of TNF-alpha production. Chem Pharm Bull (Tokyo) 2007, 55:223-226.
18. Abramo C., Meijgaarden K.E., Garcia D., Franken K.L., Klein M.R., Kolk A.J., et al. Monokine induced by interferon gamma and IFN-gamma response to a fusion protein of mycobacterium tuberculosis ESAT-6 and CFP-10 in brazilian tuberculosis patients. Microbes Infect 2006, 8:45-51.
19. Nishimoto N., Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:386-391.
20. Machado A.L., Lima L.M., Araujo J.X., Fraga C.A., Koatz V.L., Barreiro E.J. Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorg Med Chem Lett 2005, 15:1169-1172.
21. Nakamura T., Noguchi T., Kobayashi H., Miyachi H., Hashimoto Y. Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity. Chem Pharm Bull (Tokyo) 2006, 54:1709-1714.
22. Franks M.E., Macpherson G.R., Figg W.D. Thalidomide. Lancet 2004, 363:1802-1811.
23. Man H.W., Corral L.G., Stirling D.I., Muller G.W. Alpha-fluoro-substituted thalidomide analogues. Bioorg Med Chem Lett 2003, 13:3415-3417.
24. Muller G.W., Chen R., Huang S.Y., Corral L.G., Wong L.M., Patterson R.T., et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999, 9:1625-1630.
25. Muller G.W., Corral L.G., Shire M.G., Wang H., Moreira A., Kaplan G., et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996, 39:3238-3240.
26. Kim Y.S., Kim J.S., Jung H.C., Song I.S. The effects of thalidomide on the stimulation of NF-kappab activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line. Mol Cells 2004, 17:210-216.
27. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mrna degradation. J Exp Med 1993, 177:1675-1680.
28. Sampaio E.P., Hernandez M.O., Carvalho D.S., Sarno E.N. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. Leprae-induced TNFalpha production in vitro. Biomed Pharmacother 2002, 56:13-19.
29. Bauditz J., Wedel S., Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active crohn's disease. Gut 2002, 50:196-200.
30. Hata M., Sugisaki K., Miyazaki E., Kumamoto T., Tsuda T. Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers. Intern Med 2007, 46:1387-1393.
31. Ramsaransing G.S., Teelken A., Arutjunyan A.V., De Keyser J. Peripheral blood leukocyte no production in MS patients with a benign vs progressive course. Neurology 2004, 62:239-242.
32. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
33. Corral L.G., Muller G.W., Moreira A.L., Chen Y., Wu M., Stirling D., et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996, 2:506-515.
34. Zheng S.G., Wang J.H., Stohl W., Kim K.S., Gray J.D., Horwitz D.A. TGF-beta requires CTLA-4 early after T cell activation to induce foxp3 and generate adaptive CD4+CD25+regulatory cells. J Immunol 2006, 176:3321-3329.
35. Zheng Y., Manzotti C.N., Liu M., Burke F., Mead K.I., Sansom D.M. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 2004, 172:2778-2784.
36. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003, 9:606-612.
37. Giannopoulos K., Schmitt M., Wlasiuk P., Chen J., Bojarska-Junak A., Kowal M., et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008, 22:222-224.
38. Haskova Z., Izawa A., Contreras A.G., Flynn E., Boulday G., Briscoe D.M. Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation 2007, 83:1595-1601.
39. Wenzel J., Zahn S., Mikus S., Wiechert A., Bieber T., Tuting T. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br J Dermatol 2007, 157:752-757.
40. Lienenluke B., Stojanovic T., Fiebig T., Fayyazi A., Germann T., Hecker M. Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat - role of endothelial cell-leukocyte interaction. Br J Pharmacol 2001, 133:1414-1423.
41. Kimura A., Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010, 40:1830-1835.
42. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961.
43. Ogata A., Chauhan D., Teoh G., Treon S.P., Urashima M., Schlossman R.L., et al. IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997, 159:2212-2221.
44. Sampaio E.P., Kaplan G., Miranda A., Nery J.A., Miguel C.P., Viana S.M., et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993, 168:408-414.
45. Villahermosa L.G., Fajardo T.T., Abalos R.M., Balagon M.V., Tan E.V., Cellona R.V., et al. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am J Trop Med Hyg 2005, 72:518-526.